Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Biologics Market Outlook to 2015
    3.1 Market Size
    3.2 Market Segmentation
    3.3 Country Level Analysis

4. Market Trends & Drivers
    4.1 Cancer Indications Driving the Biosimilar Race
    4.2 Rising Business Alliances Aiding in Biosimilar Development
    4.3 Governments Realizing the Potential in Biosimilars, Encouraging Industry Growth
    4.4 Biosimilar Players in US to Prefer BLA over Abbreviated Pathway

5. Biosimilars Market Outlook to 2015
    5.1 Market Size
    5.2 Market Segmentation
          5.2.1 Erythropoietin
                  5.2.1.1 Scientific Insight
                  5.2.1.2 Market Analysis
                  5.2.1.3 Recent Activities
          5.2.2 Human Growth Hormone
                  5.2.2.1 Scientific Insight
                  5.2.2.2 Market Analysis
                  5.2.2.3 Recent Activities
          5.2.3 G-CSF
                  5.2.3.1 Scientific Insight
                  5.2.3.2 Market Analysis
                  5.2.3.3 Recent Activities
          5.2.4 Monoclonal Antibody
                  5.2.4.1 Scientific Insight
                  5.2.4.2 Market Analysis
                  5.2.4.3 Recent Activities
          5.2.5 Human Insulin
                  5.2.5.1 Scientific Insight
                  5.2.5.2 Market Analysis
                  5.2.5.3 Recent Activities
          5.2.6 Interferons
                  5.2.6.1 Scientific Insight
                  5.2.6.2 Market Analysis

6. Major Geographical Market
    6.1 US
          6.1.1 Market Analysis
          6.1.2 Regulatory Analysis
          6.1.3 Recent Activities
    6.2 Europe
          6.2.1 Market Analysis
          6.2.2 Regulatory Analysis
          6.2.3 Recent Activities
    6.3 India
          6.3.1 Market Analysis
          6.3.2 Regulatory Analysis
          6.3.3 Recent Activities
    6.4 China
          6.4.1 Market Analysis
          6.4.2 Regulatory Analysis
          6.4.3 Recent Activities
    6.5 Korea
          6.5.1 Market Analysis
          6.5.2 Regulatory Analysis
          6.5.3 Recent Activities

7. Competitive Landscape (Key Products and Recent Activities)
    7.1 US
          7.1.1 Hospira
    7.2 Europe
          7.2.1 Stada Arzneimittel
          7.2.2 Hexal AG
          7.2.3 Ratiopharm GmbH
          7.2.4 Sandoz GmbH
          7.2.5 Bioton
    7.3 India
          7.3.1 Dr.Reddy's Labs (DRL)
          7.3.2 Intas Pharmaceuticals Ltd.
          7.3.3 Biocon Limited
          7.3.4 Wockhardt Limited
          7.3.5 Shantha Biotechnics Limited
          7.3.6 Reliance Life Sciences
    7.4 China
          7.4.1 3 SBio Inc.
          7.4.2 Beijing Tri-Prime
          7.4.3 Beijing SL Pharmaceutical Co., Ltd.
          7.4.4 Shandong Kexing Biological Products Co., Ltd
          7.4.5 Hangzhou Jiuyuan Gene Engineering
    7.5 Korea
          7.5.1 LG Life Sciences
          7.5.2 Celltrion Pharm Inc.
          7.5.3 Dong-A Pharmaceutical Co., Ltd
    7.6 Others
          7.6.1 Teva
          7.6.2 Cangene Corporation
          7.6.3 Microbix Biosystems, Inc.